instmctions): Core B will be responsible for providing porcine models of myocardial infarction to each of the 3 projects in this PPG. Core Functions: A. To generate a pig Ml model with cardiac structural and functional derangements for all projects. B. To measure changes in cardiac structure and function after Ml. C. To treat Ml pigs (with AAV or drugs) and insert BrdU-containing minipumps as described in each of the projects, and measure the effects on cardiac structure and function. D. To provide the 3 projects with fixed tissue, isolated myocytes and frozen tissue for project specific experiments. Each of the three projects within this PPG will explore fundamental aspects of cardiac dysfunction induced by myocardial infarction in pigs. This animal model will be used because it has critical physiological features that mimic human biology. In addition, the Ml model to be used induces changes in cardiac structure and function that approximate conditions in humans with ischemic heart disease. Core B will supply investigators with a reliable, well characterized animal model so that each project can explore the mechanism they think is critical to heart failure induction and progression. Core B will also treat animals with agents that each of the 3 projects think will blunt or reverse the pathological consequences of Ml. At the completion of each study, Core B will prepare pig heart tissue (and blood) for histology, molecular biology and cell function analysis. These samples and data will be available to all projects.
This Core will establish a large animal model of cardiac dysfunction, for testing of novel therapies for ischemic heart disease. This animal model has characteristics that are similar to humans. These features of the model system should allow our results to be translated into novel therapies for patients who have had a myocardial infarction and have a poor prognosis.
|Molkentin, Jeffery D (2014) Letter by Molkentin regarding article, "The absence of evidence is not evidence of absence: the pitfalls of Cre Knock-Ins in the c-Kit Locus". Circ Res 115:e21-3|
|Hullmann, Jonathan E; Grisanti, Laurel A; Makarewich, Catherine A et al. (2014) GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. Circ Res 115:976-85|
|van Berlo, Jop H; Kanisicak, Onur; Maillet, Marjorie et al. (2014) c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509:337-41|
|Scimia, Maria C; Gumpert, Anna M; Koch, Walter J (2014) Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther 14:183-95|
|Davis, Jennifer; Molkentin, Jeffery D (2014) Myofibroblasts: trust your heart and let fate decide. J Mol Cell Cardiol 70:9-18|
|Correll, Robert N; Eder, Petra; Burr, Adam R et al. (2014) Overexpression of the Na+/K+ ATPase ?2 but not ?1 isoform attenuates pathological cardiac hypertrophy and remodeling. Circ Res 114:249-56|
|Duran, Jason M; Makarewich, Catherine A; Trappanese, Danielle et al. (2014) Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res 114:1700-12|
|Barr, Larry A; Makarewich, Catherine A; Berretta, Remus M et al. (2014) Imatinib activates pathological hypertrophy by altering myocyte calcium regulation. Clin Transl Sci 7:360-7|
|Makarewich, Catherine A; Zhang, Hongyu; Davis, Jennifer et al. (2014) Transient receptor potential channels contribute to pathological structural and functional remodeling after myocardial infarction. Circ Res 115:567-80|
|Houser, Steven R (2014) Role of RyR2 phosphorylation in heart failure and arrhythmias: protein kinase A-mediated hyperphosphorylation of the ryanodine receptor at serine 2808 does not alter cardiac contractility or cause heart failure and arrhythmias. Circ Res 114:1320-7; discussion 1327|
Showing the most recent 10 out of 19 publications